SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine (NVX)
NVX 1.035-5.5%Dec 30 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote (23)1/24/1997 10:12:00 AM
From: kech   of 35
 
Thanks Don - I must have been thinking of Smith Kline Beechem or Chiron instead of Merck. Do you have any concern that the profit stream will be big for one or two years but will be rapidly eroded by new entrants such as Chriron and and SKB? One answer might be that the rest of the vaccine pipeline will then kick in to save the day but that may be just wishful thinking? How rapidly will the pricing of NVX's DTAP vaccine have to drop once new entrants come in?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News